TABLE 2.
Patient no. | Age (yrs) | Gender | Wt (kg) | WHO stage | Size (mm2) | Lesion type | IS | Atb duration (days) | Atb regimen | Dose reduced | Rif dose (mg/kg) | Clr dose (mg/kg) | Surgery | Site of relapse | Time to relapse (days) | CS | PR |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | Male | 15 | 1 | 100 | Nodule | No | 56 | Rif-Clr | No | 10.0 | 13.3 | No | Initial site | 100 | No | No |
2 | 62 | Male | 137 | 1 | 700 | Ulcer | No | 56 | Rif-Clr | No | 4.4 | 7.3 | No | Initial site | 175 | No | Yes |
3 | 86 | Male | 99 | 3 | 6,630 | Ulcer | Yes | 84 | Rif-Clr | Yes | 3.0 | 5.1 | No | Initial site | 252 | Yes | Yes |
4 | 79 | Male | 102 | 2 | 2,500 | Ulcer | No | 56 | Rif-Clr | Yes | 5.9 | 4.9 | No | Local new lesion | 175 | No | No |
5 | 74 | Male | 106 | 2 | 2,660 | Ulcer | Yes | 70 | Rif-Clr | No | 5.7 | 9.4 | No | Initial site | 188 | Yes | Yes |
6 | 43 | Male | 95 | 1 | 484 | Ulcer | No | 56 | Rif-Clr | No | 6.3 | 10.5 | No | Initial site | 290 | No | No |
7 | 73 | Male | 112 | 3 | 572 | Nodule | No | 56 | Rif-Clr | No | 5.4 | 8.9 | No | Initial site | 270 | No | Yes |
IS, immune suppression; Rx, treatment; Atb, antibiotic; Rif, rifampin; Clr, clarithromycin; CS, corticosteroids; PR, paradoxical reaction.